A report from Citi reiterates its Buy rating and $11 price target on Anthera Pharmaceuticals ANTH.
The report states, “This morning Anthera announced positive data from an interim BCell analysis of the PEARL-SC Study. Anthera continues to remain blinded to primary efficacy data. The data indicate that weekly and monthly subQ doses of A-623 (blisibimod) result in statistically significant reductions of B-cells. We view these results as positive, given that the findings are consistent with data from previous clinical studies of A-623.”
ANTH closed yesterday at $5.82.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in